Solanezumab
- Generic Name
- Solanezumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 955085-14-0
- Unique Ingredient Identifier
- 5D6PWO0333
- Background
Solanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
- Associated Conditions
- -
- Associated Therapies
- -
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 194
- Registration Number
- NCT04623242
- Locations
- ๐บ๐ธ
University of California San Diego Medical Center, La Jolla, California, United States
๐บ๐ธWashington University in St. Louis, Saint Louis, Missouri, United States
๐บ๐ธColumbia University, New York, New York, United States
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 26
- Registration Number
- NCT02760602
- Locations
- ๐บ๐ธ
Banner Sun Health Research Institute, Sun City, Arizona, United States
๐บ๐ธCenter for Neurosciences, Tucson, Arizona, United States
๐บ๐ธArizona Health Sciences Center, Tucson, Arizona, United States
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
- Conditions
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT02614131
- Locations
- ๐บ๐ธ
Parexel Early Phase Unit at Glendale, Glendale, California, United States
๐บ๐ธCRI Lifetree, Marlton, New Jersey, United States
๐บ๐ธPRA Health Sciences, Salt Lake City, Utah, United States
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1169
- Registration Number
- NCT02008357
- Locations
- ๐บ๐ธ
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
๐บ๐ธUniversity of Kansas Hospital, Fairway, Kansas, United States
๐บ๐ธWashington University School of Medicine, Saint Louis, Missouri, United States
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2129
- Registration Number
- NCT01900665
- Locations
- ๐บ๐ธ
Neurology Center of North Orange County, Fullerton, California, United States
๐บ๐ธPharmaSite Research Inc, Baltimore, Maryland, United States
๐บ๐ธSenior Clinical Trials, Inc., Laguna Hills, California, United States
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
- First Posted Date
- 2013-01-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 490
- Registration Number
- NCT01760005
- Locations
- ๐จ๐ฆ
UBC Hospital, Vancouver, British Columbia, Canada
๐บ๐ธUniversity of Washington, Seattle, Washington, United States
๐ซ๐ทCHU de Rouen - Hรดpital Charles Nicolle, Rouen, Seine Maritime, France
A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2012-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 55
- Registration Number
- NCT01148498
- Locations
- ๐บ๐ธ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Louis, Missouri, United States
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1457
- Registration Number
- NCT01127633
- Locations
- ๐ฌ๐ง
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Camberwell, London, United Kingdom
Effect of LY2062430 on the Progression of Alzheimer's Disease
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2012-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1000
- Registration Number
- NCT00905372
- Locations
- ๐ฏ๐ต
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
Effect of LY2062430 on the Progression of Alzheimer's Disease
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2012-12-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1040
- Registration Number
- NCT00904683
- Locations
- ๐ฌ๐ง
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Swindon, Wiltshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.